Researchers sought to determine the recommended dose, safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib in patients with symptomatic untreated CLL.
TCI use also resulted in an increased risk of lymphoma in the 3 studies with topical corticosteroid comparators.
The immune cells in the microenvironment can reign in myeloma cells but become suppressed and dysregulated during disease progression.
A deepened understanding of long-term effects can help clinicians to better determine upfront therapy and monitoring strategies for pediatric patients with Hodgkin lymphoma.
Patients with MM had higher levels of lnc ANRIL compared with controls, which was associated with increased levels of beta-2 microglobulin and more advanced-stage disease.
An open-label, phase 2 trial was conducted at 10 centers in France and enrolled patients with sympotomatic, measurable newly diagnosed multiple myeloma.
Baseline alcohol consumption was associated with a higher QOL score compared with never use of alcohol.
Combination therapy of anti-PD-1 camrelizumab plus decitabine led to longer response in patients with relapsed/refractory Hodgkin lymphoma.
Researchers sought to analyze the occurrence and severity of cytokine release syndrome in patients with relapsed/refractory multiple myeloma who recieve CAR-T therapy.
The DRSS model, incorporates features related to histology, genetic profile, and treatment response.
